Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-03-15-Speech-4-118"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-03-15"^^xsd:date2
dcterms:Is Part Of	lp_eu:VOTE2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20010315.5.4-118"2
lpv:hasSubsequent	lp_eu:2001-03-15-Speech-4-1192
lpv:speaker	lp:Ilda Figueiredo2
lpv:spokenAs	substitute; Committee on Women's Rights and Equal Opportunities (1999-07-21--2002-01-14)3 member; EMPL (1999-07-21--2002-01-14)3 unknown; Partido Comunista Português (1999-07-20--2004-07-19)3 member; Delegation for relations with the Mashreq countries and the Gulf (1999-09-29--2002-01-14)3 substitute; AGRI (1999-07-21--2002-01-14)3 member; EUL/NGL (1999-07-20--2002-03-05)3
lpv:translated text	". It is important that the European Parliament states its position on the future of the biotechnology industry, not only because this will be a key industry in the future but, particularly, because of the ethical and socio-economic issues that it raises, such as those of genetics and medicines, for example, in the case of GMOs. Unfortunately, Parliament’s report, drafted by Mr Purvis, does not address these issues and, dangerously, acts as a biased mouthpiece for all the interests of the huge multinationals in the sector. It follows an approach that supports, in the name of good causes, the liberalisation and increasingly widespread use of products, not all the consequences of which for the environment and human health are known, quite apart from the fact that these actions also raise far-reaching ethical issues, such as genetic modifications and the patenting of life and the environment, which is the heritage of everyone. The approach of squeezing profit from everything, without careful assessment, leads the industry, in order to compensate for high research costs, to try to put onto the market products whose safety cannot be guaranteed and which, furthermore, create an economic dependency on the part of their users, which is what is happening in agriculture with GMOs. Furthermore, in terms of medicines and patenting them, developing countries and the poorest parts of the population are being excluded, which is what is happening, unacceptably, as a result of the behaviour of multinationals in Brazil and South Africa. I therefore reject this report. This is an area in which research should be in the public domain, not controlled by private interests, since the fair distribution of the benefits and the necessary risk assessment must be guaranteed."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph